Clinical trials
Recruiting Anemia, Refractory, with Excess of Blasts trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 2 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 19 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 3 |
| Fred Hutchinson Cancer Center | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| National Cancer Institute (NCI) | 2 |
| ARCE Therapeutics, Inc. | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Children's Hospital of Philadelphia | 1 |
| Hannah Choe, MD | 1 |
| Medical College of Wisconsin | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Refractory, with Excess of Blasts | 19 |
| Leukemia, Myeloid, Acute | 11 |
| Leukemia, Myelomonocytic, Chronic | 7 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Myelodysplastic Syndromes | 5 |
| Leukemia | 4 |
| Leukemia, Biphenotypic, Acute | 4 |
| Myeloproliferative Disorders | 4 |
| Lymphoma, Non-Hodgkin | 3 |
| Anemia, Aplastic | 2 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.